Loading clinical trials...
Loading clinical trials...
A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
Conditions
Interventions
Fimaporfin and Gemcitabine
Gemcitabine/Cisplatin chemotherapy
Locations
50
United States
City of Hope National Medical Center
Duarte, California, United States
Emory University Hospital, 1365C Clifton Road NE
Atlanta, Georgia, United States
University of Chicago Medical Center, 5841 South Maryland Avenue
Chicago, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
The Mayo Clinic Hospital - Saint Mary's Campus, 1216 Second Street Southwest
Rochester, Minnesota, United States
Baylor College of Medicine
Houston, Texas, United States
Start Date
May 23, 2019
Primary Completion Date
April 28, 2022
Completion Date
May 6, 2022
Last Updated
September 11, 2023
NCT07282912
NCT07146646
NCT04753996
NCT05430698
NCT06313203
NCT04421820
Lead Sponsor
PCI Biotech AS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions